Keywords: Human Genome Sciences, Benlysta, Sales, Priority goals, Lupus, Raxibacumab

Human Genome Sciences’ Benlysta sales disappoint

Article | 11 January 2012

US biotech firm Human Genome Sciences (Nasdaq: HGSI) president and chief executive Thomas Watkins yesterday highlighted priority goals for 2012 and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Human Genome Sciences

Go to company listing

Related Drugs

Benlysta

raxibacumab

Go to drug listing